You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The strategic alliance gives Ambry's sequencing customers use of the NextGENe analysis software.
Athena alleges that Ambry's sale of tests for certain types of diabetes infringes on patents that Athena licensed from its development partner Correlagen.
Ambry was certified to use the SureSelect target enrichment technology for next-gen sequencing services.
Genedata, Ambry Genetics, Arrayit, NanoInk
The company passed certification for using Agilent's arrays for genomics researchers.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.